Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients

Johannis A van Rossum1, Anke Vennegoor, Lisanne Balk

  • 1Department of Neurology (MS Center Amsterdam), VU University Medical Center, The Netherlands.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|July 6, 2013
PubMed

Insights

JC virus (JCV) positivity increases anxiety in multiple sclerosis patients on natalizumab but rarely impacts treatment continuation. Most patients remain on natalizumab despite JCV seropositivity, indicating manageable risk perception.

Area of Science:

  • Neuroimmunology
  • Viral Infections
  • Clinical Therapeutics

Background:

  • Natalalizumab is effective for multiple sclerosis (MS) but carries a risk of progressive multifocal leukoencephalopathy (PML).
  • JC virus (JCV) carriership is a primary risk factor for natalizumab-associated PML.
  • Limited data exist on how JCV serostatus influences patient decisions regarding natalizumab treatment.

Purpose of the Study:

  • To assess the impact of JCV seropositivity on patient anxiety and safety perceptions.
  • To evaluate the effect of JCV seropositivity on the willingness to continue natalizumab therapy.
  • To analyze decisional conflict related to natalizumab treatment in JCV-positive MS patients.

Main Methods:

  • Utilized visual analog scales for safety feelings.
  • Employed the Hospital Anxiety and Depression Scale (HADS) to measure anxiety.
  • Administered a decisional conflict scale to assess treatment continuation.
  • Correlated JCV serostatus with psychological and treatment adherence outcomes.

Main Results:

  • JCV seropositivity significantly elevated anxiety levels concerning PML risk (p = 0.004).
  • Despite increased anxiety, only 3% of patients in the cohort discontinued natalizumab due to JCV positivity.
  • No significant impact on overall treatment continuation was observed solely based on JCV positivity.

Conclusions:

  • JCV seropositivity is associated with heightened anxiety regarding PML in MS patients on natalizumab.
  • Natalalizumab treatment continuation is generally maintained by patients even when aware of JCV seropositivity.
  • Risk-benefit communication strategies may effectively manage patient concerns and support ongoing natalizumab therapy.

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Arboviral Encephalitis01:25

Arboviral Encephalitis

Arboviral encephalitis refers to brain inflammation caused by arthropod-borne viruses, particularly those transmitted through mosquito vectors. Among these, West Nile virus (WNV), a member of the Flaviviridae family, is a significant public health concern. WNV is an enveloped, positive-sense, single-stranded RNA virus. Human infection typically begins when an infected mosquito introduces the virus into the dermis during feeding. The primary transmission cycle involves birds as amplifying hosts...
Encephalitis l: Introduction01:19

Encephalitis l: Introduction

Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...